Coronavirus: DCGI approves Corbevax for children!- Watch Video

India's drug regulator granted final approval to Biological E's COVID-19 vaccine Corbevax, which is India's first indigenously developed RBD protein sub-unit vaccine against COVID-19, for children between 12-18 years of age.

This is the third COVID-19 vaccine to be approved for children between 12 and 18 years of age after Bharat Biotech's Covaxin and Cadila Healthcare’s ZyCoV-D.

"Biological E Limited's Corbevax vaccine, India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against COVID-19, has received emergency use authorisation (EUA) from India's drug regulator for the 12 to 18-year age group," the company said in a statement.

Mahima Datla, Managing Director, Biological E. Limited, said, "...We truly believe that with this approval, we are even more closer to finishing our global fight against the COVID-19 pandemic. Once fully-vaccinated, children can resume their activities and educational pursuits in schools & colleges without any apprehension. We thank all the participants in the clinical trials, Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology, Govt of India, Translational Health Science and Technology Institute (TSTHI) and the principal investigators and clinical site staff who have extended their support during the last several months."